Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients
Phase 2
- Conditions
- COVIDE-19.B97.29Other coronavirus as the cause of diseases classified elsewhere
- Registration Number
- IRCT20200310046736N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
COVID-19 Patients who have the clinical signs of COVIDE-19 infection such as fever, cough, sputum production, sore throat, and so on.
Patients with the positive CT scan
Patients who declare Informed Consent for this study.
Exclusion Criteria
Pregnant Women (based on WHO protocol)
Lactating Women (based on WHO protocol)
Individuals who exhibit specific allergic reactions to intravenous administration.
Patients with/or with a history of dangerous underlying diseases such as IgA deficiency
Patients with/or with a history of dangerous diseases such as cardiovascular and or hematological disorders (hemophilia, thalassemia, leukemia).
Patients with/or with a history of underlying diseases such as liver and kidney disease
Smokers
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan.
- Secondary Outcome Measures
Name Time Method Recovery and normal levels of biomarkers associated COVID-19. Timepoint: At least 1 to 2 weeks after treatment. Method of measurement: Laboratory Techniques.